-
1.发明授权LYMPHOTOXIN-BETA, LYMPHOTOXIN-BETA COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF 失效淋巴毒素β，淋巴毒素β复杂，药物制剂和用途及其治疗
公开(公告)号：EP0672143B1
公开(公告)日：2008-06-04
申请号：EP94907045.2
申请日：1993-12-02
发明人： BROWNING, Jeffrey , WARE, Carl F.
CPC分类号： C07K14/525 , A61K38/00
摘要： This invention relates to lymphotoxin- beta , a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin- beta and other peptides such as lymphotoxin- alpha and to complexes comprising multiple subunits of lymphotoxin- beta . These proteins and complexes are useful in holding LT- alpha formed within the cell on the cell surface where the LT- alpha /LT- beta complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT- alpha /LT- beta complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT- beta .
-
公开(公告)号：EP0536299B1
公开(公告)日：2001-06-06
申请号：EP91913174.8
申请日：1991-06-27
发明人： BROWNING, Jeffrey , WARE, Carl, F.
CPC分类号： C07K14/5255 , A61K38/00 , C07K14/525
摘要： This invention relates to a membrane associated protein, p33, and the complex it forms with a soluble lymphotoxin. These proteins are found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. These proteins and complexes are useful as anti-inflammatory agents, enhancers of tumor infiltrating lymphocytes, tumor growth inhibiting agents, T cell inhibiting agents and T cell activating agents.
-
公开(公告)号：EP0536299A1
公开(公告)日：1993-04-14
申请号：EP91913174.0
申请日：1991-06-27
发明人： BROWNING, Jeffrey , WARE, Carl, F.
IPC分类号： A61K35 , A61K38 , A61K39 , A61K45 , A61P29 , A61P31 , A61P35 , A61P37 , A61P43 , C07K1 , C07K14 , C07K16 , C07K19 , C12N5 , C12N15 , C12P21
CPC分类号： C07K14/5255 , A61K38/00 , C07K14/525
摘要： Protéine p33 associée à une membrane et le complexe qu'elle forme avec une lymphotoxine soluble. On trouve ces protéines sur la surface d'un certain nombre de cellules, y compris des cellules d'hybridome II-23.D7 de lymphosites T stimulées par un ester de phorbol (PMA). Ces protéines et ces complexes sont utiles en temps qu'agents anti-inflammatoires, activateurs de lymphosites s'infiltrant dans des tumeurs, agents inhibants la croissance de tumeur, agents d'inhibitions de lymphosites T et agents d'activation de lymphosites T.
-
4.发明公开LYMPHOTOXIN-$g(b), LYMPHOTOXIN-$g(b) COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF 失效淋巴毒素β，淋巴毒素β复杂，药物制剂和用途及其治疗。
公开(公告)号：EP0672143A1
公开(公告)日：1995-09-20
申请号：EP94907045.0
申请日：1993-12-02
发明人： BROWNING, Jeffrey , WARE, Carl F.
IPC分类号： C12N15 , A61K38 , A61K39 , A61P29 , A61P31 , A61P35 , A61P37 , A61P43 , C07H21 , C07K14 , C07K19 , C12N5 , C12P21 , C12R1
CPC分类号： C07K14/525 , A61K38/00
摘要： This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.
-
5.发明公开TREATMENT OF DEMYELINATING DISORDERS WITH SOLUBLE LYMPHOTOXIN-BETA-RECEPTOR 审中-公开治疗与可溶性淋巴毒素β受体脱髓鞘疾病的
公开(公告)号：EP2073833A2
公开(公告)日：2009-07-01
申请号：EP07868490.9
申请日：2007-10-18
IPC分类号： A61K38/17 , A61M3/00 , A61K39/395 , A61P25/00
CPC分类号： A61K38/1793 , C07K14/70578 , C07K2319/30
摘要： The invention relates to the treatment of demyelinating disorders, e.g. multiple sclerosis, using a soluble lymphotoxin beta receptor (LTβR) as an inhibitor of the lymphotoxin pathway.
-
6.发明授权
公开(公告)号：EP0954333B1
公开(公告)日：2006-06-28
申请号：EP97913798.1
申请日：1997-10-24
申请人： Biogen Idec MA Inc.
IPC分类号： A61K39/395 , A61K38/17 , A61K38/55 , C07K19/00
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7151 , C07K16/241 , C07K16/2878 , C07K2319/00 , C07K2319/30 , Y02A50/401 , Y02A50/414
摘要： Compositions and methods comprising "lymphotoxin- beta receptor blocking agents" which block lymphotoxin-ss receptor signalling and are useful for altering immunological diseases, and particularly antibody mediated immune responses.
-
公开(公告)号：EP1317283B1
公开(公告)日：2011-07-06
申请号：EP01968799.5
申请日：2001-09-12
申请人： Biogen Idec MA Inc.
IPC分类号： A61K39/395 , A61K38/17 , A61P35/00
CPC分类号： C07K16/2878 , A61K38/00 , A61K2039/505 , C07K2317/73
摘要： The present invention relates to methods of modulating angiogenesis and inhibiting tumor progression by using TWEAK receptor (Fn14) agonists. In particular, methods for inhibiting angiogenesis are disclosed.
-
公开(公告)号：EP1210425B1
公开(公告)日：2007-04-25
申请号：EP00957502.8
申请日：2000-08-16
发明人： MACKAY, Fabienne , BROWNING, Jeffrey , AMBROSE, Christine , TSCHOPP, Jurg , SCHNEIDER, Pascal , THOMPSON, Jeffrey
IPC分类号： C12N15/12 , C07K14/715 , A61K38/17 , A61K39/395
CPC分类号： C07K14/7151 , A61K38/17 , A61K39/00 , A61K39/395 , A61K2039/505 , C07K14/70575 , C07K16/241 , C07K2319/00
摘要： Receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
-
9.发明授权A METHOD FOR THE HIGH LEVEL EXPRESSION OF THE ACTIVE FORM OF LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN FUSION PROTEINS AND THEIR PURIFICATION 有权方法为淋巴毒素β受体免疫球蛋白融合蛋白及其清洁活性形式的高表达
公开(公告)号：EP1141248B1
公开(公告)日：2011-12-07
申请号：EP99967350.2
申请日：1999-12-16
申请人： Biogen Idec MA Inc.
IPC分类号： C07K14/705 , C07K19/00 , C12N5/10 , A61K38/17
CPC分类号： C12P21/00 , A61K38/00 , C07K14/70578 , C07K14/7151 , C07K2319/00 , C12P21/02
摘要： The invention relates to methods for the expression of high yields of the form protein-immunoglobulin fusions having high affinity binding to its ligand, by culturing hosts transformed with DNA encoding the desired fusions in a cultutre system at a low temperature thereby minimizing the amount of misfolded or misbridged protein forms. Said host cells may be transformed mammalian, insect, yeast or bacterial cells. The protein-immunoglobulin fusion may comprises a member of the TNF or TNF-receptor family, such as lymphotoxin-beta or lymphotoxin-beta receptor. The invention also relates to pharmaceutical composition comprising said protein-immunoglobulin fusions.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
